here is more the pharmacovigilance working party of the committee for medicinal products for human use chmp considered safety of atomoxetine in january and advised that the overall balance of risks and benefits of atomoxetine remained positive in its licensed indication but recommended that the amendments to the product information included the potential risk of seizures and qt prolongation